Financial Performance - Total revenue for the year ended December 31, 2025, was RMB 651.9 million, representing a year-on-year increase of 5.0% compared to RMB 620.7 million in 2024[3] - Gross profit for the same period was RMB 170.2 million, up 6.2% from RMB 160.2 million in 2024[3] - Adjusted net profit for the year was RMB 4.1 million, a significant improvement of 112.9% compared to an adjusted net loss of RMB 31.5 million in 2024[3] - Total revenue increased from approximately RMB 620.7 million in 2024 to approximately RMB 651.9 million in 2025, representing a growth of 5.0%[22] - Revenue from pharmaceutical health product sales rose from approximately RMB 426.5 million in 2024 to approximately RMB 442.9 million in 2025, marking a growth of 3.9%[22] - Revenue from digital healthcare solutions reached RMB 208.9 million, an increase of 7.6% from RMB 194.2 million in 2024[4] - The company reported a net loss attributable to shareholders of RMB 72,986 thousand for 2025, an improvement from a loss of RMB 107,687 thousand in 2024, representing a reduction of 32.2%[71] - The basic loss per share improved to RMB (0.24) in 2025 from RMB (0.37) in 2024, indicating a 35.1% decrease in loss per share[71] Revenue Breakdown - Revenue from pharmaceutical health products sales was RMB 442.9 million, reflecting a growth of 3.9% from RMB 426.5 million in 2024[4] - Revenue from digital healthcare solutions reached RMB 208.9 million, an increase of 7.6% from RMB 194.2 million in 2024[4] - Digital healthcare solutions revenue reached RMB 208.9 million, a year-on-year increase of 7.6%, accounting for 32.1% of total revenue in 2025, up from 31.3% in 2024[17] - Revenue from digital healthcare solutions increased by 7.6% from approximately RMB 194.2 million for the year ending December 31, 2024, to approximately RMB 208.9 million for the year ending December 31, 2025[23] Operational Metrics - The platform has expanded its service coverage to over 260 cities nationwide, connecting more than 45,125 healthcare institutions, a year-on-year growth of 1.18%[5] - The registered individual user base reached 61.1 million, marking a 13.12% increase year-on-year, with an average of 3.3 million monthly active users for the year[5] - The company has established partnerships with over 905,900 healthcare professionals, including approximately 47,800 registered doctors[5] - The total number of employees as of December 31, 2025, was 487, with 23.82% in sales and marketing, and 18.69% in R&D[44] Cost and Expenses - Cost of sales rose by 4.6% from approximately RMB 460.5 million for the year ending December 31, 2024, to approximately RMB 481.7 million for the year ending December 31, 2025[24] - Sales and marketing expenses decreased by 25.4% from approximately RMB 117.3 million for the year ending December 31, 2024, to approximately RMB 87.5 million for the year ending December 31, 2025[26] - Administrative expenses increased by 22.2% from approximately RMB 93.0 million for the year ending December 31, 2024, to approximately RMB 113.6 million for the year ending December 31, 2025[27] - Research and development expenses decreased by 30.8% from approximately RMB 50.5 million for the year ending December 31, 2024, to approximately RMB 35.0 million for the year ending December 31, 2025[28] Cash Flow and Financial Position - Cash and cash equivalents increased from approximately RMB 58.3 million as of December 31, 2024, to approximately RMB 398.8 million as of December 31, 2025[36] - The net cash used in operating activities for the year ended December 31, 2025, was RMB (114,438) thousand, compared to RMB (56,047) thousand in 2024, indicating a significant increase in cash outflow[37] - The company achieved a net increase in cash and cash equivalents of RMB 340,540 thousand for the year ended December 31, 2025, compared to RMB 711 thousand in 2024[37] - The debt-to-asset ratio improved to 69.2% as of December 31, 2025, down from 129.7% as of December 31, 2024, primarily due to increased capital raised post-IPO[42] - The total assets increased to RMB 759,927 thousand as of December 31, 2025, compared to RMB 297,773 thousand as of December 31, 2024[47] Strategic Initiatives - The digital healthcare solutions segment is identified as a strategic growth engine, driving future revenue growth and enhancing service capabilities[7] - The company aims to enhance operational efficiency through the integration of AI applications, upgrading its platform to improve patient experience and operational management for healthcare institutions[12] - The company plans to launch the AI hospital solution in 2025, integrating AI tools for patient management and operational efficiency[13] - The introduction of the Blue Spirit Control GPT product focuses on automatic risk management in healthcare, enhancing infection control and clinical decision-making[15] - A digital supply chain upgrade will be implemented, enhancing procurement decision-making and online sales services for corporate clients[19] - Continued investment in AI research and development will target high-frequency demand scenarios in the healthcare sector[21] - The company is committed to optimizing existing business structures and accelerating the deployment of AI technologies in healthcare services[20] - The digital hospital solutions will enhance resource allocation and response speed in healthcare institutions, improving overall service quality[14] Shareholder Information - The company did not declare any dividends for the years ended December 31, 2025, and 2024[73] - The company has no significant contingent liabilities or pledged assets as of December 31, 2025[40][41] Governance and Compliance - The company has adopted the corporate governance code as per the Hong Kong Stock Exchange listing rules, ensuring compliance since its listing date on September 17, 2025[78] - The audit committee has reviewed the financial reporting procedures and risk management practices of the group[89] - The external auditor has confirmed that the financial data in the preliminary performance announcement aligns with the draft consolidated financial statements[90] - No significant events have occurred after the reporting period and up to the date of this announcement[87]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 160 Health International Limited 健 康 160 國 際 有限公司 董事會召開日期 健康160国际有限公司（「本公司」，連同其附屬公司及合併附屬實體，統稱「本集 團」）董事（「董事」）會（「董事會」）謹此宣佈，董事會會議將於2026年3月27日（星期 五）舉行，藉以（其中包括）考慮及批准本集團截至2025年12月31日止年度的全年業 績及其發佈，並考慮建議派發末期股息（如有）。 承董事會命 健康160国际有限公司 羅寧政先生 董事長、執行董事兼首席執行官 （於開曼群島註冊成立之有限公司） （股份代號：2656） 香港，2026年3月17日 於本公告日期，董事會包括：(i)執行董事羅寧政先生、冀翠琳先生、黃浪先生及 王立法先生；(ii)非執行董事劉海濱先生及孫萌女士；及(iii)獨立非執行董事王歡先 生、徐衛國博士及范明博士。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 160 Health International Limited 健 康 160 國 際 有限公司 （於開曼群島註冊成立之有限公司） （股份代號：2656） 本年度經調整淨利潤（非國際財務報告準則計量）轉虧為盈，主要歸因於以下各項綜 合影響：(i)收入實現同比增長，帶動毛利微幅增加；及(ii)通過精細化管理及運營效 率持續提升，本年度運營開支總額（包括銷售及營銷、研發及行政開支）大幅減少。 – 1 – 董事會謹此強調，國際財務報告準則並未對「經調整淨利潤」作出界定。本集團將其 界定為加回(i)以股份為基礎的薪酬開支，及(ii)上市開支（統稱為「經調整項目」）而 對年內利潤作出調整後的金額。其中，以股份為基礎的薪酬開支屬非現金項目，不 影響期內現金流量及核心業務經營。董事會認為，經調整淨利潤剔除了經調整項目 （屬非營運性質且未必反映本集團之實際營運表現）的潛在影響，有助於向潛在投資 者及其他人士提供了解及 ...

健 康 160 國 際 有限公司 本公告乃由健康160國際有限公司（「本公司」）自願作出，旨在告知其股東及潛在投 資者，其控股股東（即羅寧政先生、LNZ Management Limited及Luo Holdings Limited）已延長禁售期。 （於開曼群島註冊成立之有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 （股份代號：2656） 自願公告 控股股東自願延長禁售期 160 Health International Limited 承董事會命 健康160國際有限公司 羅寧政先生 董事長、執行董事兼首席執行官 香港，2026年3月13日 茲提述本公司日期為2025年9月9日之招股章程（「招股章程」）。除非另有界定，本公 告所用詞彙與招股章程所界定者具有相同涵義。 誠如招股章程所披露，根據上市規則第10.07條，各控股股東已承諾，除根據全球發 售外，其不得：(a)自招股章程日期起至上市日期起計滿六個月之日止期間（「首六個 月期間」）， ...

Group 1 - Zhaoyi Innovation (03986) saw an intraday increase of 1.72% amid rising shipping risks in the Hormuz Strait affecting the supply chain of key raw materials like helium [1] - Rongchang Bio (09995) rose over 3.6% after its RC288 injection application was accepted by NMPA, showing excellent anti-tumor activity and safety in preclinical studies [1] - Swire Properties (01972) increased by over 2.2% following the release of its 2025 full-year results, reporting revenue of HKD 16.041 billion, a year-on-year increase of 11%, and a basic earnings per share of HKD 1.49 [1] Group 2 - Health 160 (02656) surged over 10%, reaching a new high of HKD 140.5, with a nearly doubled stock price since March 9, despite a previous drop of about 30% on February 11 [2] - Gaming stocks collectively rose, with notable increases in companies like Boyaa Interactive (00434) up 4.44% and Tencent (00700) up 1.1%, following Apple's announcement of a commission rate adjustment for the App Store in mainland China [2] - Qidian Guofeng (01280) experienced a significant rise of over 26% after announcing a sales contract for AI servers with an independent third party [2] Group 3 - Hong Kong bank stocks fell again, with Standard Chartered (02888) down 4.67% and HSBC Holdings (00005) down 3.8%, amid ongoing tensions in the Middle East affecting transactions involving Asian balance sheets [3] - Cement stocks saw a general increase, with China National Building Material (03323) up 2.62%, as construction activity picked up post-Lantern Festival, leading to a steady recovery in cement market demand [3] - Domestic property stocks rebounded, with CIFI Holdings (00884) up 2.9% and Sunac China (01918) up 5.45%, as recent data indicated a 3.3% year-on-year decline in second-hand housing listings in Shenzhen [4] Group 4 - Yao Cai Securities (01428) saw a significant rise of over 39% after extending the acquisition offer deadline with Ant Group to March 25, 2026 [4] - PayPay (PAYP.US), a digital wallet operator backed by SoftBank, debuted on the US stock market with a 13.5% increase, achieving a market cap of nearly USD 12 billion [5] - Chinese electric vehicle companies NIO (NIO.US) and Xpeng Motors (XPEV.US) saw stock increases of 1.46% and 3.58%, respectively, amid discussions of potential collaborations with European automotive giant Stellantis [5] Group 5 - Storage stocks collectively declined, with SanDisk (SNDK.US) down 5.59% and Micron Technology (MU.US) down 3.19%, following negative sentiment from short-seller Citron Capital [6] - Optical communication stocks fell, with Applied Optoelectronics (AAOI.US) down 16.39%, despite securing a bulk order for a new data center transceiver [6] - Agricultural input stocks continued to rise, with CF Industries Holdings (CF.US) up 13.21%, driven by supply chain disruptions in the Middle East affecting fertilizer transportation [7] Group 6 - Oil stocks rose sharply, with Battalion Oil (BATL.US) up 15.48% as international oil prices surged, with WTI crude rising over 8% to USD 94.66 [8] - EHang Intelligent (EH.US) reported total revenue of RMB 509.5 million (approximately USD 72.9 million) for the fiscal year 2025, marking an 11.7% year-on-year increase, despite a net loss of RMB 231 million [8]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 董事會謹此強調，本公告所披露的業務最新進展僅反映本公司部分業務的表現，並 不代表本公司總體業務表現，且未來業務發展受市場環境、行業政策、實際執行等 多種因素影響，存在不確定性。本公告所載數據無意作為，亦不應詮釋為本公司 2025年度整體業績的盈利預測或明示、暗示或代表本公司於2025年度的整體盈利狀 況。本公司尚未獲得有關2025年度整體業績的最終確切數字，2025年度整體業績或 需進一步調整及落實，可能與本公告所披露者有所不同，相關具體財務數據以本公 司後續披露的經審計2025年度業績公告為準。 （於開曼群島註冊成立之有限公司） （股份代號：2656） 自願公告 — 業務簽約的最新進展 本公告乃由健康160國際有限公司（「本公司」，連同其附屬公司及合併附屬實體統稱 為「本集團」）自願作出，旨在向本公司股東（「股東」）及潛在投資者告知本集團的最 新業務發展情況。 本公司董事（「董事」）會（「董事會」）欣 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 160 Health International Limited 健 康 160 國 際 有限公司 （於開曼群島註冊成立之有限公司） （股份代號：2656） 在對外賦能的同時，本集團亦將AI智能體全面引入內部運營，目前已應用於產品研 發、內容產出及客戶服務體系，產品迭代週期已縮短超過60%。同時，本集團已完 成OpenClaw的部署並持續完善相關應用，內部效率的提升亦顯著加快了為醫療機 構部署交付的速度。 – 1 – 本集團始終堅持安全至上的原則，所有對外應用及內部部署的AI智能體，均由內部 專業技術團隊實施全流程安全加固，確保系統運行安全、穩定。未來，本集團將憑 藉真實的醫患交互場景與成熟的平台化運營能力，持續探索OpenClaw等AI智能體 在醫療健康領域的深度應用，致力為股東創造長期價值。 承董事會命 健康160國際有限公司 自願公告 業務更新 本公告乃由健康160國際有限公司（「本公司」，連同其 ...

160 Health International Limited 健 康 160 國 際 有限公司 （於開曼群島註冊成立之有限公司） （股份代號：2656） 董事名單與其角色和職能 健康160国际有限公司董事（「董事」）會（「董事會」）成員載列如下： 執行董事 羅寧政先生 （董事長） 冀翠琳先生 黃浪先生 王立法先生 非執行董事 劉海濱先生 孫萌女士 獨立非執行董事 王歡先生 徐衛國博士 范明博士 董事會已設立三個委員會。各董事委員會的成員載列如下： | | 委員會 | | | | | --- | --- | --- | --- | --- | | 董事 | | 審核委員會 | 薪酬委員會 | 提名委員會 | | 羅寧政先生 | | — | 成員 | 主席 | | 冀翠琳先生 | | — | — | — | | 黃浪先生 | | — | — | — | | 王立法先生 | | — | — | — | | 劉海濱先生 | | 成員 | — | — | | 孫萌女士 | | — | — | 成員 | | 王歡先生 | | 主席 | 成員 | 成員 | | 徐衛國博士 | | 成員 | 主席 | 成員 | | 范明 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 160 Health International Limited 健 康 160 國 際 有限公司 （於開曼群島註冊成立之有限公司） （股份代號：2656） 非執行董事變動 及 – 1 – 劉先生的簡歷詳情如下： 劉海濱先生，46歲，於2002年7月取得吉林大學地質礦產勘查學士學位。劉先生擁 有超過20年的互聯網產品研發與大型平台服務經驗，曾服務於數億量級用戶。劉先 生現任本公司高級產品及運營總監及本公司附屬公司深圳市寧遠科技股份有限公司 監事。在加入本公司前，他曾擔任迅雷有限公司（一間於美國納斯達克證券交易所 上市的公司，股份代號：XNET）的核心產品項目負責人。 自2015年加入本公司以來，劉先生深耕互聯網醫療行業超過十年，主導研發並打造 了包括雲醫院、醫患IM、大數據平台、推薦算法平台及AI產品在內的多項核心產 品與基礎設施。劉先生成功將互聯網的尖端技術、產品方法論及運營體系與醫療健 康行業進行深 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 健康160国际有限公司 FF301 第 1 頁 共 10 頁 v 1.2.0 FF301 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 1. 股份分類 普通股 股份類別 不適用 於香港聯交所上市 (註1) 是 證券代號 (如上市) 02656 說明 已發行股份（不包括庫存股份）數目 庫存股份數目 已發行股份總數 上月底結存 336,452,810 0 336,452,810 增加 / 減少 (-) 0 0 本月底結存 336,452,810 0 336,452,810 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02656 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | ...